Literature DB >> 26622324

Hyperuricaemia with deposition: latest evidence and therapeutic approach.

Fernando Perez-Ruiz1, Estibaliz Marimon2, Sandra P Chinchilla3.   

Abstract

This article reviews recent evidence on urate deposition and the opportunity for a therapeutic approach. We reviewed Pubmed 2013-2015 literature using the search terms 'deposition' with 'hyperuricaemia', 'gout', 'ultrasonography', 'DECT' (dual-energy computed tomography), 'radiography', 'CT'(computed tomography), 'MRI' (magnetic resonance imaging), or 'cardiovascular', in addition to a digital bibliographic library compiled by the authors with 2072 papers on hyperuricaemia and gout. Relevant papers on the topic were selected. Recent evidence, mostly based on imaging studies, showed a continuum from hyperuricaemia to deposition and clinical manifestations. Chronic inflammation and structural damage may be present even in asymptomatic patients with crystal-proved deposition. The impact of early intervention in patients with asymptomatic deposition either on vascular outcomes or further structural joint damage has not been demonstrated yet. In conclusion, a worldwide definition of gout is still lacking, stages from hyperuricaemia to clinical gout not being definitively defined. Although there is increasing interest on the impact of early deposits on joint damage and cardiovascular outcomes, robust evidence is still lacking to fully support interventions.

Entities:  

Keywords:  deposition; dual-energy computed tomography; gout; gout suppressant; hyperuricaemia; ultrasonography

Year:  2015        PMID: 26622324      PMCID: PMC4637846          DOI: 10.1177/1759720X15599734

Source DB:  PubMed          Journal:  Ther Adv Musculoskelet Dis        ISSN: 1759-720X            Impact factor:   5.346


  57 in total

1.  Systemic staging for urate crystal deposits with dual-energy CT and ultrasound in patients with suspected gout.

Authors:  Alexander Huppertz; Kay-Geert A Hermann; Torsten Diekhoff; Moritz Wagner; Bernd Hamm; Wolfgang A Schmidt
Journal:  Rheumatol Int       Date:  2014-03-12       Impact factor: 2.631

2.  Gout, allopurinol intake and clinical outcomes in the hospitalized multimorbid elderly.

Authors:  Carlotta Franchi; Francesco Salerno; Alessio Conca; Codjo D Djade; Mauro Tettamanti; Luca Pasina; Salvatore Corrao; Alessandra Marengoni; Maura Marcucci; Pier Mannuccio Mannucci; Alessandro Nobili
Journal:  Eur J Intern Med       Date:  2014-10-22       Impact factor: 4.487

3.  [Influence of the natural history of disease on a previous diagnosis in patients with gout].

Authors:  Fernando Pérez Ruiz; Jesús Ruiz López; Ana María Herrero Beites
Journal:  Reumatol Clin       Date:  2009-05-22

4.  Suboptimal physician adherence to quality indicators for the management of gout and asymptomatic hyperuricaemia: results from the UK General Practice Research Database (GPRD).

Authors:  T R Mikuls; J T Farrar; W B Bilker; S Fernandes; K G Saag
Journal:  Rheumatology (Oxford)       Date:  2005-05-03       Impact factor: 7.580

5.  Validation of a radiographic damage index in chronic gout.

Authors:  Nicola Dalbeth; Barnaby Clark; Fiona McQueen; Anthony Doyle; William Taylor
Journal:  Arthritis Rheum       Date:  2007-08-15

6.  Ultrasonographic measurement of tophi as an outcome measure for chronic gout.

Authors:  Fernando Perez-Ruiz; Iñaki Martin; Begoña Canteli
Journal:  J Rheumatol       Date:  2007-07-15       Impact factor: 4.666

7.  Persistence of monosodium urate crystals and low-grade inflammation in the synovial fluid of patients with untreated gout.

Authors:  E Pascual
Journal:  Arthritis Rheum       Date:  1991-02

8.  Tophi and frequent gout flares are associated with impairments to quality of life, productivity, and increased healthcare resource use: Results from a cross-sectional survey.

Authors:  Puja P Khanna; George Nuki; Thomas Bardin; Anne-Kathrin Tausche; Anna Forsythe; Amir Goren; Jeffrey Vietri; Dinesh Khanna
Journal:  Health Qual Life Outcomes       Date:  2012-09-22       Impact factor: 3.186

Review 9.  A review of uric acid, crystal deposition disease, and gout.

Authors:  Fernando Perez-Ruiz; Nicola Dalbeth; Tomas Bardin
Journal:  Adv Ther       Date:  2014-12-23       Impact factor: 3.845

Review 10.  Allopurinol hypersensitivity: a systematic review of all published cases, 1950-2012.

Authors:  Sheena N Ramasamy; Cameron S Korb-Wells; Diluk R W Kannangara; Myles W H Smith; Nan Wang; Darren M Roberts; Garry G Graham; Kenneth M Williams; Richard O Day
Journal:  Drug Saf       Date:  2013-10       Impact factor: 5.228

View more
  7 in total

1.  Systematic Structure-Activity Relationship (SAR) Exploration of Diarylmethane Backbone and Discovery of A Highly Potent Novel Uric Acid Transporter 1 (URAT1) Inhibitor.

Authors:  Wenqing Cai; Jingwei Wu; Wei Liu; Yafei Xie; Yuqiang Liu; Shuo Zhang; Weiren Xu; Lida Tang; Jianwu Wang; Guilong Zhao
Journal:  Molecules       Date:  2018-01-27       Impact factor: 4.411

Review 2.  Asymptomatic hyperuricaemia: a silent activator of the innate immune system.

Authors:  Leo A B Joosten; Tania O Crişan; Petter Bjornstad; Richard J Johnson
Journal:  Nat Rev Rheumatol       Date:  2019-12-10       Impact factor: 20.543

3.  Effects of Shizhifang on NLRP3 Inflammasome Activation and Renal Tubular Injury in Hyperuricemic Rats.

Authors:  Yansheng Wu; Fei He; Yingqiao Li; Huiling Wang; Liqiang Shi; Qiang Wan; Jiaoying Ou; Xiaoying Zhang; Di Huang; Lin Xu; Pinglan Lin; Guanghui Yang; Liqun He; Jiandong Gao
Journal:  Evid Based Complement Alternat Med       Date:  2017-11-12       Impact factor: 2.629

4.  Identification of C21orf59 and ATG2A as novel determinants of renal function-related traits in Japanese by exome-wide association studies.

Authors:  Yoshiji Yamada; Jun Sakuma; Ichiro Takeuchi; Yoshiki Yasukochi; Kimihiko Kato; Mitsutoshi Oguri; Tetsuo Fujimaki; Hideki Horibe; Masaaki Muramatsu; Motoji Sawabe; Yoshinori Fujiwara; Yu Taniguchi; Shuichi Obuchi; Hisashi Kawai; Shoji Shinkai; Seijiro Mori; Tomio Arai; Masashi Tanaka
Journal:  Oncotarget       Date:  2017-07-11

Review 5.  A glance into the future of gout.

Authors:  Francisca Sivera; Mariano Andres; Nicola Dalbeth
Journal:  Ther Adv Musculoskelet Dis       Date:  2022-07-28       Impact factor: 3.625

Review 6.  Role of microRNA alternation in the pathogenesis of gouty arthritis.

Authors:  Zhipan Luo; Fan Yang; Shaocheng Hong; Jianpeng Wang; Bangjie Chen; Liangyun Li; Junfa Yang; Yan Yao; Chenchen Yang; Ying Hu; Shuxian Wang; Tao Xu; Jun Wu
Journal:  Front Endocrinol (Lausanne)       Date:  2022-08-11       Impact factor: 6.055

7.  Circulating microRNA alternations in primary hyperuricemia and gout.

Authors:  Jana Bohatá; Veronika Horváthová; Markéta Pavlíková; Blanka Stibůrková
Journal:  Arthritis Res Ther       Date:  2021-07-10       Impact factor: 5.156

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.